Aquestive Therapeutics Stock News

An investigation on behalf of investors in Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares over potential wrongdoing at Aquestive Therapeutics, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 03/09/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Aquestive Therapeutics, Inc. (NASDAQ: AQST officers and directors breached their fiduciary duties and caused damage to the company and its shareholders. On March 1, 2021, a lawsuit was filed against Aquestive Therapeutics, Inc over alleged securities laws violations. The plaintiff claimed that between December 2, 2019 and September 25, 2020, the Defendants made materially false and misleading statements regarding the Company''s business, operational and compliance policies.

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2021 Results - Earnings Call Transcript

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Aquestive Therapeutics press release (AQST): FY GAAP EPS of -$1.85 misses by $0.36.Revenue of $50.83M (+10.9% Y/Y) beats by $1.73M.

WARREN, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care a

WARREN, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients'' problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent developments in its business.

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas

Jazz (JAZZ) delivered earnings and revenue surprises of 13.48% and 4.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

WARREN, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care

In last trading session, Aquestive Therapeutics Inc. (NASDAQ:AQST) saw 0.56 million shares changing hands with its beta currently measuring 3.35. Company’s recent per share price level of $2.78 trading at $0.3 or 12.10% at ring of the bell on the day assigns it a market valuation of $119.85M. That closing price of AQST’s stock is … Aquestive Therapeutics Inc. (NASDAQ:AQST) Climbs 36.60% In 2022; Are Investors Attracted By Its $2.78 Price? Read More »

Aquestive Therapeutics Inc (NASDAQ: AQST ) announced positive topline results from Part 1 of the EPIPHAST study for its AQST-109 epinephrine oral film. Part 1 showed that key pharmacokinetic measures were aligned with previous favorable results for AQST-109 and that the product was well tolerated with no serious adverse events. A lead candidate is currently being evaluated in Part 2 of the EPIPHAST … Full story available on Benzinga.com

Aquestive Therapeutics (AQST) is trading ~6% higher in the premarket Friday after the commercial-stage pharmaceutical company announced positive topline data from its Part 1 of the…

ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?